The immunopathogenesis of narcolepsy type 1.
Journal
Nature reviews. Immunology
ISSN: 1474-1741
Titre abrégé: Nat Rev Immunol
Pays: England
ID NLM: 101124169
Informations de publication
Date de publication:
03 Jul 2023
03 Jul 2023
Historique:
accepted:
01
06
2023
medline:
4
7
2023
pubmed:
4
7
2023
entrez:
3
7
2023
Statut:
aheadofprint
Résumé
Narcolepsy type 1 (NT1) is a chronic sleep disorder resulting from the loss of a small population of hypothalamic neurons that produce wake-promoting hypocretin (HCRT; also known as orexin) peptides. An immune-mediated pathology for NT1 has long been suspected given its exceptionally tight association with the MHC class II allele HLA-DQB1*06:02, as well as recent genetic evidence showing associations with polymorphisms of T cell receptor genes and other immune-relevant loci and the increased incidence of NT1 that has been observed after vaccination with the influenza vaccine Pandemrix. The search for both self-antigens and foreign antigens recognized by the pathogenic T cell response in NT1 is ongoing. Increased T cell reactivity against HCRT has been consistently reported in patients with NT1, but data demonstrating a primary role for T cells in neuronal destruction are currently lacking. Animal models are providing clues regarding the roles of autoreactive CD4
Identifiants
pubmed: 37400646
doi: 10.1038/s41577-023-00902-9
pii: 10.1038/s41577-023-00902-9
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023. Springer Nature Limited.
Références
Schenck, C. H., Bassetti, C. L., Arnulf, I. & Mignot, E. English translations of the first clinical reports on narcolepsy and cataplexy by Westphal and Gélineau in the late 19th century, with commentary. J. Clin. Sleep. Med. 3, 301–311 (2007).
pubmed: 17561602
pmcid: 2564780
doi: 10.5664/jcsm.26804
Aserinsky, E. & Kleitman, N. Regularly occurring periods of eye motility, and concomitant phenomena, during sleep. Science 118, 273–274 (1953).
pubmed: 13089671
doi: 10.1126/science.118.3062.273
Mignot, E. Genetic and familial aspects of narcolepsy. Neurology 50, S16–S22 (1998).
pubmed: 9484418
doi: 10.1212/WNL.50.2_Suppl_1.S16
Roberts, M. H. & Erdei, E. Comparative United States autoimmune disease rates for 2010-2016 by sex, geographic region, and race. Autoimmun. Rev. 19, 102423 (2020).
pubmed: 31733367
doi: 10.1016/j.autrev.2019.102423
Economo, C. & Newman, K. O. Encephalitis lethargica: its sequelae and treatment (Oxford University Press, 1931).
de Lecea, L. et al. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc. Natl Acad. Sci. USA 95, 322–327 (1998).
pubmed: 9419374
pmcid: 18213
doi: 10.1073/pnas.95.1.322
Peyron, C. et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat. Med. 6, 991–997 (2000).
pubmed: 10973318
doi: 10.1038/79690
Thannickal, T. C. et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron 27, 469–474 (2000).
pubmed: 11055430
pmcid: 8760623
doi: 10.1016/S0896-6273(00)00058-1
Nishino, S., Ripley, B., Overeem, S., Lammers, G. J. & Mignot, E. Hypocretin (orexin) deficiency in human narcolepsy. Lancet 355, 39–40 (2000). This study is the first to show that the cause of NT1 is a loss of hypocretin transmission.
pubmed: 10615891
doi: 10.1016/S0140-6736(99)05582-8
Mignot, E. et al. The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch. Neurol. 59, 1553–1562 (2002).
pubmed: 12374492
doi: 10.1001/archneur.59.10.1553
Honda, M. et al. Absence of ubiquitinated inclusions in hypocretin neurons of patients with narcolepsy. Neurology 73, 511–517 (2009).
pubmed: 19687452
pmcid: 2730798
doi: 10.1212/WNL.0b013e3181b2a6af
Sakurai, T. et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 92, 573–585 (1998).
pubmed: 9491897
doi: 10.1016/S0092-8674(00)80949-6
Peyron, C. et al. Neurons containing hypocretin (orexin) project to multiple neuronal systems. J. Neurosci. 18, 9996–10015 (1998).
pubmed: 9822755
pmcid: 6793310
doi: 10.1523/JNEUROSCI.18-23-09996.1998
Marcus, J. N. et al. Differential expression of orexin receptors 1 and 2 in the rat brain. J. Comp. Neurol. 435, 6–25 (2001).
pubmed: 11370008
doi: 10.1002/cne.1190
Willie, J. T. et al. Distinct narcolepsy syndromes in orexin receptor-2 and orexin null mice: molecular genetic dissection of non-REM and REM sleep regulatory processes. Neuron 38, 715–730 (2003).
pubmed: 12797957
doi: 10.1016/S0896-6273(03)00330-1
Evans, R. et al. Orexin 2 receptor-selective agonist danavorexton improves narcolepsy phenotype in a mouse model and in human patients. Proc. Natl Acad. Sci. USA 119, e2207531119 (2022).
pubmed: 35994639
pmcid: 9436334
doi: 10.1073/pnas.2207531119
Andlauer, O. et al. Predictors of hypocretin (orexin) deficiency in narcolepsy without cataplexy. Sleep 35, 1247–1255F (2012).
pubmed: 22942503
pmcid: 3413802
doi: 10.5665/sleep.2080
Postiglione, E. et al. Narcolepsy with intermediate cerebrospinal level of hypocretin-1. Sleep 45, zsab285 (2022).
pubmed: 34902030
doi: 10.1093/sleep/zsab285
Dalmau, J. & Graus, F. Antibody-mediated neuropsychiatric disorders. J. Allergy Clin. Immunol. 149, 37–40 (2022).
pubmed: 34800433
doi: 10.1016/j.jaci.2021.11.008
Rose, N. R. & Bona, C. Defining criteria for autoimmune diseases (Witebsky’s postulates revisited). Immunol. Today 14, 426–430 (1993).
pubmed: 8216719
doi: 10.1016/0167-5699(93)90244-F
Juji, T., Satake, M., Honda, Y. & Doi, Y. HLA antigens in Japanese patients with narcolepsy: all the patients were DR2 positive. Tissue Antigens 24, 316–319 (1984).
pubmed: 6597978
doi: 10.1111/j.1399-0039.1984.tb02144.x
Mignot, E. et al. Complex HLA-DR and -DQ interactions confer risk of narcolepsy-cataplexy in three ethnic groups. Am. J. Hum. Genet. 68, 686–699 (2001).
pubmed: 11179016
pmcid: 1274481
doi: 10.1086/318799
Han, F. et al. HLA-DQ association and allele competition in Chinese narcolepsy. Tissue Antigens 80, 328–335 (2012).
pubmed: 22862152
doi: 10.1111/j.1399-0039.2012.01948.x
Han, F. et al. HLA DQB1*06:02 negative narcolepsy with hypocretin/orexin deficiency. Sleep 37, 1601–1608 (2014).
pubmed: 25197808
pmcid: 4173917
doi: 10.5665/sleep.4066
Ollila, H. M. et al. HLA-DPB1 and HLA class I confer risk of and protection from narcolepsy. Am. J. Hum. Genet. 96, 136–146 (2015).
pubmed: 25574827
pmcid: 4289679
doi: 10.1016/j.ajhg.2014.12.010
Pelin, Z., Guilleminault, C., Risch, N., Grumet, F. C. & Mignot, E. HLA-DQB1*0602 homozygosity increases relative risk for narcolepsy but not disease severity in two ethnic groups. US Modafinil in Narcolepsy Multicenter Study Group. Tissue Antigens 51, 96–100 (1998).
pubmed: 9459509
doi: 10.1111/j.1399-0039.1998.tb02952.x
Donner, H. et al. MHC diversity in Caucasians, investigated using highly heterogeneous noncoding sequence motifs at the DQB1 locus including a retroviral long terminal repeat element, and its comparison to nonhuman primate homologues. Immunogenetics 51, 898–904 (2000).
pubmed: 11003383
doi: 10.1007/s002510000222
Otting, N. et al. The orthologs of HLA-DQ and -DP genes display abundant levels of variability in macaque species. Immunogenetics 69, 87–99 (2017).
pubmed: 27771735
doi: 10.1007/s00251-016-0954-6
Petersdorf, E. W. et al. HLA-DQ heterodimers in hematopoietic cell transplantation. Blood 139, 3009–3017 (2022).
pubmed: 35271697
pmcid: 9121842
doi: 10.1182/blood.2022015860
Hohjoh, H., Terada, N., Honda, Y., Juji, T. & Tokunaga, K. Negative association of the HLA-DRB1*1502-DQB1*0601 haplotype with human narcolepsy. Immunogenetics 52, 299–301 (2001).
pubmed: 11220634
doi: 10.1007/s002510000269
Hor, H. et al. Genome-wide association study identifies new HLA class II haplotypes strongly protective against narcolepsy. Nat. Genet. 42, 786–789 (2010).
pubmed: 20711174
doi: 10.1038/ng.647
Sharon, E. et al. Genetic variation in MHC proteins is associated with T cell receptor expression biases. Nat. Genet. 48, 995–1002 (2016).
pubmed: 27479906
pmcid: 5010864
doi: 10.1038/ng.3625
Ishigaki, K. et al. HLA autoimmune risk alleles restrict the hypervariable region of T cell receptors. Nat. Genet. 54, 393–402 (2022).
pubmed: 35332318
pmcid: 9010379
doi: 10.1038/s41588-022-01032-z
Roh, E. Y. et al. Association of HLA-DR and -DQ genes with narcolepsy in Koreans: comparison with two control groups, randomly selected subjects and DRB1*1501-DQB1*0602–positive subjects. Hum. Immunol. 67, 749–755 (2006).
pubmed: 17002906
doi: 10.1016/j.humimm.2006.03.024
Han, F. et al. Genome wide analysis of narcolepsy in China implicates novel immune loci and reveals changes in association prior to versus after the 2009 H1N1 influenza pandemic. PLoS Genet. 9, e1003880 (2013).
pubmed: 24204295
pmcid: 3814311
doi: 10.1371/journal.pgen.1003880
Miyagawa, T. et al. New susceptibility variants to narcolepsy identified in HLA class II region. Hum. Mol. Genet. 24, 891–898 (2015).
pubmed: 25256355
doi: 10.1093/hmg/ddu480
Tafti, M. et al. Narcolepsy-associated HLA class I alleles implicate cell-mediated cytotoxicity. Sleep 39, 581–587 (2016).
pubmed: 26518595
pmcid: 4763366
doi: 10.5665/sleep.5532
Liu, W.-X., Jiang, Y., Hu, Q.-X. & You, X.-B. HLA-DRB1 shared epitope allele polymorphisms and rheumatoid arthritis: a systemic review and meta-analysis. Clin. Invest. Med. 39, E182–E203 (2016).
pubmed: 27917778
doi: 10.25011/cim.v39i6.27487
Hollenbach, J. A. & Oksenberg, J. R. The immunogenetics of multiple sclerosis: a comprehensive review. J. Autoimmun. 64, 13–25 (2015).
pubmed: 26142251
pmcid: 4687745
doi: 10.1016/j.jaut.2015.06.010
Beecham, A. H. et al. Ancestral risk modification for multiple sclerosis susceptibility detected across the major histocompatibility complex in a multi-ethnic population. PLoS ONE 17, e0279132 (2022).
pubmed: 36548255
pmcid: 9778564
doi: 10.1371/journal.pone.0279132
Erlichster, M. et al. Improved HLA-based prediction of coeliac disease identifies two novel genetic interactions. Eur. J. Hum. Genet. 28, 1743–1752 (2020).
pubmed: 32733071
pmcid: 7785002
doi: 10.1038/s41431-020-0700-2
Karell, K. et al. HLA types in celiac disease patients not carrying the DQA1*05-DQB1*02 (DQ2) heterodimer: results from the European Genetics Cluster on Celiac Disease. Hum. Immunol. 64, 469–477 (2003).
pubmed: 12651074
doi: 10.1016/S0198-8859(03)00027-2
Shi, T. et al. HLA-DQ genotype distribution and risk evaluation of celiac disease in Northwest China. Scand. J. Gastroenterol. 58, 471–476 (2022).
pubmed: 36415137
doi: 10.1080/00365521.2022.2147801
Hallmayer, J. et al. Narcolepsy is strongly associated with the T-cell receptor alpha locus. Nat. Genet. 41, 708–711 (2009).
pubmed: 19412176
pmcid: 2803042
doi: 10.1038/ng.372
Tafti, M. et al. DQB1 locus alone explains most of the risk and protection in narcolepsy with cataplexy in Europe. Sleep 37, 19–25 (2014).
pubmed: 24381371
pmcid: 3865351
doi: 10.5665/sleep.3300
Faraco, J. et al. ImmunoChip study implicates antigen presentation to T cells in narcolepsy. PLoS Genet. 9, e1003270 (2013).
pubmed: 23459209
pmcid: 3573113
doi: 10.1371/journal.pgen.1003270
Ollila, H. M. et al. Narcolepsy risk loci outline role of T cell autoimmunity and infectious triggers in narcolepsy. Nat. Commun. 14, 2709 (2023). This large genetic study identifies seven new loci associated with risk of NT1 and pinpoints the involvement of genetic risk loci for NT1 in T cell and dendritic cell biology.
pubmed: 37188663
pmcid: 10185546
doi: 10.1038/s41467-023-36120-z
Simmons, K. M. et al. Failed genetic protection: type 1 diabetes in the presence of HLA-DQB1*06:02. Diabetes 69, 1763–1769 (2020).
pubmed: 32439825
pmcid: 7372070
doi: 10.2337/db20-0038
Dauvilliers, Y. et al. Increased risk of narcolepsy in children and adults after pandemic H1N1 vaccination in France. Brain 136, 2486–2496 (2013).
pubmed: 23884811
doi: 10.1093/brain/awt187
Sarkanen, T. O., Alakuijala, A. P. E., Dauvilliers, Y. A. & Partinen, M. M. Incidence of narcolepsy after H1N1 influenza and vaccinations: systematic review and meta-analysis. Sleep. Med. Rev. 38, 177–186 (2018). This comprehensive meta-analysis concludes that within the first year following Pandemrix vaccination, the relative risk of NT1 was increased 5–14-fold in children and adolescents and 2–7-fold in adults.
pubmed: 28847694
doi: 10.1016/j.smrv.2017.06.006
Jacob, L. et al. Comparison of Pandemrix and Arepanrix, two pH1N1 AS03-adjuvanted vaccines differentially associated with narcolepsy development. Brain Behav. Immun. 47, 44–57 (2015).
pubmed: 25452148
doi: 10.1016/j.bbi.2014.11.004
Ambati, A. et al. Mass spectrometric characterization of narcolepsy-associated pandemic 2009 influenza vaccines. Vaccines 8, 630 (2020).
pubmed: 33142956
pmcid: 7712488
doi: 10.3390/vaccines8040630
Wimmers, F. et al. The single-cell epigenomic and transcriptional landscape of immunity to influenza vaccination. Cell 184, 3915–3935.e21 (2021).
pubmed: 34174187
pmcid: 8316438
doi: 10.1016/j.cell.2021.05.039
Buonocore, S. M. & van der Most, R. G. Narcolepsy and H1N1 influenza immunology a decade later: what have we learned? Front. Immunol. 13, 902840 (2022).
pubmed: 36311717
pmcid: 9601309
doi: 10.3389/fimmu.2022.902840
Canelle, Q., Dewé, W., Innis, B. L. & van der Most, R. Evaluation of potential immunogenicity differences between Pandemrix
pubmed: 27105343
pmcid: 5027709
doi: 10.1080/21645515.2016.1168954
Montplaisir, J. et al. Risk of narcolepsy associated with inactivated adjuvanted (AS03) A/H1N1 (2009) pandemic influenza vaccine in Quebec. PLoS ONE 9, e108489 (2014).
pubmed: 25264897
pmcid: 4180737
doi: 10.1371/journal.pone.0108489
Wu, H. et al. Symptoms and occurrences of narcolepsy: a retrospective study of 162 patients during a 10-year period in eastern China. Sleep. Med. 15, 607–613 (2014).
pubmed: 24767723
doi: 10.1016/j.sleep.2013.12.012
Han, F. et al. Narcolepsy onset is seasonal and increased following the 2009 H1N1 pandemic in China. Ann. Neurol. 70, 410–417 (2011).
pubmed: 21866560
doi: 10.1002/ana.22587
Huang, W.-T. et al. Narcolepsy and 2009 H1N1 pandemic vaccination in Taiwan. Sleep. Med. 66, 276–281 (2020).
pubmed: 30579702
doi: 10.1016/j.sleep.2018.10.036
Simakajornboon, N. et al. Increased incidence of pediatric narcolepsy following the 2009 H1N1 pandemic: a report from the pediatric working group of the sleep research network. Sleep 45, zsac137 (2022).
pubmed: 35695235
doi: 10.1093/sleep/zsac137
Zhang, Z. et al. New 2013 incidence peak in childhood narcolepsy: more than vaccination? Sleep 44, zsaa172 (2021).
pubmed: 32909046
doi: 10.1093/sleep/zsaa172
Edwards, K. et al. Meeting report narcolepsy and pandemic influenza vaccination: What we know and what we need to know before the next pandemic? A report from the 2nd IABS meeting. Biologicals 60, 1–7 (2019).
pubmed: 31130313
pmcid: 6668612
doi: 10.1016/j.biologicals.2019.05.005
Sturkenboom, M. C. J. M. The narcolepsy-pandemic influenza story: can the truth ever be unraveled? Vaccine 33, B6–B13 (2015).
pubmed: 26022571
doi: 10.1016/j.vaccine.2015.03.026
Shubin, M., Lebedev, A., Lyytikäinen, O. & Auranen, K. Revealing the true incidence of pandemic A(H1N1)pdm09 influenza in Finland during the first two seasons — an analysis based on a dynamic transmission model. PLoS Comput. Biol. 12, e1004803 (2016).
pubmed: 27010206
pmcid: 4807082
doi: 10.1371/journal.pcbi.1004803
Conway, J. M. et al. Vaccination against 2009 pandemic H1N1 in a population dynamical model of Vancouver, Canada: timing is everything. BMC Public Health 11, 932 (2011).
pubmed: 22168242
pmcid: 3280345
doi: 10.1186/1471-2458-11-932
Graham, M. et al. Nationwide molecular surveillance of pandemic H1N1 influenza A virus genomes: Canada, 2009. PLoS ONE 6, e16087 (2011).
pubmed: 21249207
pmcid: 3017559
doi: 10.1371/journal.pone.0016087
Picchioni, D., Hope, C. R. & Harsh, J. R. A case-control study of the environmental risk factors for narcolepsy. Neuroepidemiology 29, 185–192 (2007).
pubmed: 18043003
doi: 10.1159/000111581
Aran, A. et al. Elevated anti-streptococcal antibodies in patients with recent narcolepsy onset. Sleep 32, 979–983 (2009).
pubmed: 19725248
pmcid: 2717204
doi: 10.1093/sleep/32.8.979
Ding, Q. et al. Anti-streptococcal antibodies in Chinese patients with type -1 narcolepsy. Sleep. Med. 72, 37–40 (2020).
pubmed: 32540635
doi: 10.1016/j.sleep.2020.03.019
Longstreth, W. T., Ton, T. G. N. & Koepsell, T. D. Narcolepsy and streptococcal infections. Sleep 32, 1548 (2009).
pubmed: 20041589
pmcid: 2786037
doi: 10.1093/sleep/32.12.1548
Natori, Y. et al. Risk of immunotherapy-related narcolepsy in genetically predisposed patients: a case report of narcolepsy after administration of pembrolizumab. J. Immunother. Cancer 8, e001164 (2020).
pubmed: 33004543
pmcid: 7534705
doi: 10.1136/jitc-2020-001164
Vogrig, A. et al. Increased frequency of anti-Ma2 encephalitis associated with immune checkpoint inhibitors. Neurol. Neuroimmunol. Neuroinflamm. 6, e604 (2019).
pubmed: 31454760
pmcid: 6705619
doi: 10.1212/NXI.0000000000000604
Dalmau, J. et al. Clinical analysis of anti-Ma2-associated encephalitis. Brain 127, 1831–1844 (2004).
pubmed: 15215214
doi: 10.1093/brain/awh203
Yshii, L. M., Hohlfeld, R. & Liblau, R. S. Inflammatory CNS disease caused by immune checkpoint inhibitors: status and perspectives. Nat. Rev. Neurol. 13, 755–763 (2017).
pubmed: 29104289
doi: 10.1038/nrneurol.2017.144
Chemelli, R. M. et al. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 98, 437–451 (1999).
pubmed: 10481909
doi: 10.1016/S0092-8674(00)81973-X
Hara, J. et al. Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity. Neuron 30, 345–354 (2001).
pubmed: 11394998
doi: 10.1016/S0896-6273(01)00293-8
Tabuchi, S. et al. Conditional ablation of orexin/hypocretin neurons: a new mouse model for the study of narcolepsy and orexin system function. J. Neurosci. 34, 6495–6509 (2014).
pubmed: 24806676
pmcid: 4012309
doi: 10.1523/JNEUROSCI.0073-14.2014
Gerashchenko, D. et al. Relationship between CSF hypocretin levels and hypocretin neuronal loss. Exp. Neurol. 184, 1010–1016 (2003).
pubmed: 14769395
doi: 10.1016/S0014-4886(03)00388-1
Zhang, S. et al. The development of hypocretin (orexin) deficiency in hypocretin/ataxin-3 transgenic rats. Neuroscience 148, 34–43 (2007).
pubmed: 17618058
doi: 10.1016/j.neuroscience.2007.05.029
Tesoriero, C. et al. H1N1 influenza virus induces narcolepsy-like sleep disruption and targets sleep-wake regulatory neurons in mice. Proc. Natl Acad. Sci. USA 113, E368–E377 (2016).
pubmed: 26668381
doi: 10.1073/pnas.1521463112
Bernard-Valnet, R. et al. CD8 T cell-mediated killing of orexinergic neurons induces a narcolepsy-like phenotype in mice. Proc. Natl Acad. Sci. USA 113, 10956–10961 (2016).
pubmed: 27621438
pmcid: 5047186
doi: 10.1073/pnas.1603325113
Bernard-Valnet, R. et al. Influenza vaccination induces autoimmunity against orexinergic neurons in a mouse model for narcolepsy. Brain 145, 2018–2030 (2022). Using a transgenic mouse model, this work reveals synergy between autoreactive CD4
pubmed: 35552381
doi: 10.1093/brain/awab455
Frieser, D. et al. Tissue-resident CD8
pubmed: 35417189
doi: 10.1126/scitranslmed.abl6157
Attfield, K. E., Jensen, L. T., Kaufmann, M., Friese, M. A. & Fugger, L. The immunology of multiple sclerosis. Nat. Rev. Immunol. 22, 734–750 (2022).
pubmed: 35508809
doi: 10.1038/s41577-022-00718-z
Kornum, B. R. in Handbook of Clinical Neurology vol. 181 (eds Swaab, D. F. et al.) 161–172 (Elsevier, 2021).
Latorre, D., Sallusto, F., Bassetti, C. L. A. & Kallweit, U. Narcolepsy: a model interaction between immune system, nervous system, and sleep-wake regulation. Semin. Immunopathol. 44, 611–623 (2022).
pubmed: 35445831
pmcid: 9519713
doi: 10.1007/s00281-022-00933-9
Hartmann, F. J. et al. High-dimensional single-cell analysis reveals the immune signature of narcolepsy. J. Exp. Med. 213, 2621–2633 (2016).
pubmed: 27821550
pmcid: 5110028
doi: 10.1084/jem.20160897
Lecendreux, M. et al. Narcolepsy type 1 is associated with a systemic increase and activation of regulatory T cells and with a systemic activation of global T cells. PLoS ONE 12, e0169836 (2017).
pubmed: 28107375
pmcid: 5249232
doi: 10.1371/journal.pone.0169836
Nguyen, X.-H. et al. Circulating follicular helper T cells exhibit reduced ICOS expression and impaired function in narcolepsy type 1 patients. J. Autoimmun. 94, 134–142 (2018).
pubmed: 30104107
doi: 10.1016/j.jaut.2018.07.021
Moresco, M. et al. Flow cytometry analysis of T-cell subsets in cerebrospinal fluid of narcolepsy type 1 patients with long-lasting disease. Sleep. Med. 44, 53–60 (2018).
pubmed: 29530370
doi: 10.1016/j.sleep.2017.11.1150
Kornum, B. R. et al. Cerebrospinal fluid cytokine levels in type 1 narcolepsy patients very close to onset. Brain Behav. Immun. 49, 54–58 (2015).
pubmed: 25771509
pmcid: 4567452
doi: 10.1016/j.bbi.2015.03.004
Ramberger, M. et al. CD4
pubmed: 28364420
doi: 10.1093/sleep/zsw070
Kornum, B. R. et al. Absence of autoreactive CD4
pubmed: 28601291
doi: 10.1016/j.jneuroim.2017.05.001
Latorre, D. et al. T cells in patients with narcolepsy target self-antigens of hypocretin neurons. Nature 562, 63–68 (2018). This work uses a sensitive experimental approach to quantify and characterize rare autoreactive T cells targeting neuronal antigens in the blood and CSF of patients with NT1, providing the first solid evidence of an autoimmune process.
pubmed: 30232458
doi: 10.1038/s41586-018-0540-1
Liblau, R. S. Put to sleep by immune cells. Nature 562, 46–48 (2018).
pubmed: 30275550
doi: 10.1038/d41586-018-06666-w
Luo, G. et al. Autoimmunity to hypocretin and molecular mimicry to flu in type 1 narcolepsy. Proc. Natl Acad. Sci. USA 115, E12323–E12332 (2018).
pubmed: 30541895
pmcid: 6310865
doi: 10.1073/pnas.1818150116
Jiang, W. et al. In vivo clonal expansion and phenotypes of hypocretin-specific CD4
pubmed: 31748512
pmcid: 6868281
doi: 10.1038/s41467-019-13234-x
Vuorela, A. et al. Enhanced influenza A H1N1 T cell epitope recognition and cross-reactivity to protein-O-mannosyltransferase 1 in Pandemrix-associated narcolepsy type 1. Nat. Commun. 12, 2283 (2021).
pubmed: 33863907
pmcid: 8052463
doi: 10.1038/s41467-021-22637-8
Luo, G., Yogeshwar, S., Lin, L. & Mignot, E. J.-M. T cell reactivity to regulatory factor X4 in type 1 narcolepsy. Sci. Rep. 11, 7841 (2021).
pubmed: 33837283
pmcid: 8035403
doi: 10.1038/s41598-021-87481-8
Pedersen, N. W. et al. CD8
pubmed: 30783092
pmcid: 6381094
doi: 10.1038/s41467-019-08774-1
Cao, Y. et al. Functional inflammatory profiles distinguish myelin-reactive T cells from patients with multiple sclerosis. Sci. Transl. Med. 7, 287ra74 (2015).
pubmed: 25972006
pmcid: 4497538
doi: 10.1126/scitranslmed.aaa8038
Yu, W. et al. Clonal deletion prunes but does not eliminate self-specific αβ CD8
pubmed: 25992863
pmcid: 4455602
doi: 10.1016/j.immuni.2015.05.001
Cogswell, A. C. et al. Children with narcolepsy type 1 have increased T‐cell responses to orexins. Ann. Clin. Transl. Neurol. 6, 2566–2572 (2019).
pubmed: 31730293
pmcid: 6917326
doi: 10.1002/acn3.50908
Schinkelshoek, M. S. et al. H1N1 hemagglutinin-specific HLA-DQ6-restricted CD4
pubmed: 31048269
doi: 10.1016/j.jneuroim.2019.04.009
Beltrán, E. et al. Shared T cell receptor chains in blood memory CD4
pubmed: 30948158
doi: 10.1016/j.jaut.2019.03.010
Viste, R. et al. Narcolepsy type 1 patients have lower levels of effector memory CD4
pubmed: 34388506
doi: 10.1016/j.sleep.2021.07.024
Luo, G., Zhang, J., Lin, L. & Mignot, E. J.-M. Characterization of T cell receptors reactive to HCRT
pubmed: 35914171
pmcid: 9371724
doi: 10.1073/pnas.2205797119
Dudek, M. et al. Auto-aggressive CXCR6
pubmed: 33762736
doi: 10.1038/s41586-021-03233-8
Dayan, C. M. et al. Preventing type 1 diabetes in childhood. Science 373, 506–510 (2021).
pubmed: 34326231
doi: 10.1126/science.abi4742
Léger, J., Delcour, C. & Carel, J.-C. Fetal and neonatal thyroid dysfunction. J. Clin. Endocrinol. Metab. 107, 836–846 (2022).
pubmed: 34636892
doi: 10.1210/clinem/dgab747
Merz, W. M., Fischer-Betz, R., Hellwig, K., Lamprecht, G. & Gembruch, U. Pregnancy and autoimmune disease. Dtsch. Arztebl Int. 119, 145–156 (2022).
pubmed: 34874264
Black, J. L. et al. Analysis of hypocretin (orexin) antibodies in patients with narcolepsy. Sleep 28, 427–431 (2005).
pubmed: 16171287
doi: 10.1093/sleep/28.4.427
Overeem, S. et al. Immunohistochemical screening for autoantibodies against lateral hypothalamic neurons in human narcolepsy. J. Neuroimmunol. 174, 187–191 (2006).
pubmed: 16563524
doi: 10.1016/j.jneuroim.2006.02.010
Tanaka, S., Honda, Y., Inoue, Y. & Honda, M. Detection of autoantibodies against hypocretin, hcrtr1, and hcrtr2 in narcolepsy: anti-Hcrt system antibody in narcolepsy. Sleep 29, 633–638 (2006).
pubmed: 16774153
doi: 10.1093/sleep/29.5.633
Knudsen, S., Mikkelsen, J. D. & Jennum, P. Antibodies in narcolepsy-cataplexy patient serum bind to rat hypocretin neurons. Neuroreport 18, 77–79 (2007).
pubmed: 17259865
doi: 10.1097/WNR.0b013e328010baad
Martínez-Rodríguez, J. E., Sabater, L., Graus, F., Iranzo, A. & Santamaria, J. Evaluation of hypothalamic-specific autoimmunity in patients with narcolepsy. Sleep 30, 27–28 (2007).
pubmed: 17310861
doi: 10.1093/sleep/30.1.27
Deloumeau, A. et al. Increased immune complexes of hypocretin autoantibodies in narcolepsy. PLoS ONE 5, e13320 (2010).
pubmed: 20967199
pmcid: 2954157
doi: 10.1371/journal.pone.0013320
Lin, L. et al. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 98, 365–376 (1999).
pubmed: 10458611
doi: 10.1016/S0092-8674(00)81965-0
Ahmed, S. S. et al. Antibodies to influenza nucleoprotein cross-react with human hypocretin receptor 2. Sci. Transl. Med. 7, 294ra105 (2015).
pubmed: 26136476
doi: 10.1126/scitranslmed.aab2354
Luo, G. et al. Absence of anti-hypocretin receptor 2 autoantibodies in post Pandemrix narcolepsy cases. PLoS ONE 12, 1–25 (2017).
doi: 10.1371/journal.pone.0187305
Melén, K. et al. No evidence of autoimmunity to human OX1 or OX2 orexin receptors in Pandemrix-vaccinated narcoleptic children. J. Transl. Autoimmun. 3, 100055 (2020).
pubmed: 32743535
pmcid: 7388359
doi: 10.1016/j.jtauto.2020.100055
Lind, A. et al. Screening for autoantibody targets in post-vaccination narcolepsy using proteome arrays. Scand. J. Immunol. 91, e12864 (2020).
pubmed: 32056243
doi: 10.1111/sji.12864
Cvetkovic-Lopes, V. et al. Elevated Tribbles homolog 2-specific antibody levels in narcolepsy patients. J. Clin. Invest. 120, 713–719 (2010).
pubmed: 20160349
pmcid: 2827962
doi: 10.1172/JCI41366
Toyoda, H. et al. Anti-Tribbles homolog 2 autoantibodies in Japanese patients with narcolepsy. Sleep 33, 875–878 (2010).
pubmed: 20614847
pmcid: 2894429
doi: 10.1093/sleep/33.7.875
Kawashima, M. et al. Anti-Tribbles homolog 2 (TRIB2) autoantibodies in narcolepsy are associated with recent onset of cataplexy. Sleep 33, 869–874 (2010).
pubmed: 20614846
pmcid: 2894428
doi: 10.1093/sleep/33.7.869
Wallenius, M. et al. Autoantibodies in Pandemrix®-induced narcolepsy: nine candidate autoantigens fail the conformational autoantibody test. Autoimmunity 52, 185–191 (2019). This study illustrates how findings of autoantibodies in patients with NT1 have been difficult to replicate.
pubmed: 31328572
doi: 10.1080/08916934.2019.1643843
Lind, A. et al. A/H1N1 antibodies and TRIB2 autoantibodies in narcolepsy patients diagnosed in conjunction with the Pandemrix vaccination campaign in Sweden 2009–2010. J. Autoimmun. 50, 99–106 (2014).
pubmed: 24485154
doi: 10.1016/j.jaut.2014.01.031
Bergman, P. et al. Narcolepsy patients have antibodies that stain distinct cell populations in rat brain and influence sleep patterns. Proc. Natl Acad. Sci. USA 111, E3735–E3744 (2014).
pubmed: 25136085
pmcid: 4156690
doi: 10.1073/pnas.1412189111
Sadam, H. et al. Prostaglandin D2 receptor DP1 antibodies predict vaccine-induced and spontaneous narcolepsy type 1: large-scale study of antibody profiling. EBioMedicine 29, 47–59 (2018).
pubmed: 29449194
pmcid: 5925455
doi: 10.1016/j.ebiom.2018.01.043
Saariaho, A.-H. et al. Autoantibodies against ganglioside GM3 are associated with narcolepsy-cataplexy developing after Pandemrix vaccination against 2009 pandemic H1N1 type influenza virus. J. Autoimmun. 63, 68–75 (2015).
pubmed: 26227560
doi: 10.1016/j.jaut.2015.07.006
Zandian, A. et al. Whole-proteome peptide microarrays for profiling autoantibody repertoires within multiple sclerosis and narcolepsy. J. Proteome Res. 16, 1300–1314 (2017).
pubmed: 28121444
doi: 10.1021/acs.jproteome.6b00916
Wei, S.-C. C. et al. Tribbles 2 (Trib2) is a novel regulator of Toll-like receptor 5 signaling. Inflamm. Bowel Dis. 18, 877–888 (2012).
pubmed: 22271508
doi: 10.1002/ibd.22883
Eder, K. et al. Tribbles-2 is a novel regulator of inflammatory activation of monocytes. Int. Immunol. 20, 1543–1550 (2008).
pubmed: 18952906
pmcid: 2638877
doi: 10.1093/intimm/dxn116
Smith, A. J. F., Jackson, M. W., Neufing, P., McEvoy, R. D. & Gordon, T. P. A functional autoantibody in narcolepsy. Lancet 364, 2122–2124 (2004).
pubmed: 15589310
doi: 10.1016/S0140-6736(04)17553-3
Orjatsalo, M., Partinen, E., Wallukat, G., Alakuijala, A. & Partinen, M. Activating autoantibodies against G protein-coupled receptors in narcolepsy type 1. Sleep. Med. 77, 82–87 (2021).
pubmed: 33341642
doi: 10.1016/j.sleep.2020.11.038
Katzav, A. et al. Passive transfer of narcolepsy: anti-TRIB2 autoantibody positive patient IgG causes hypothalamic orexin neuron loss and sleep attacks in mice. J. Autoimmun. 45, 24–30 (2013).
pubmed: 23834844
doi: 10.1016/j.jaut.2013.06.010
Tanaka, S. et al. Anti-Tribbles pseudokinase 2 (TRIB2)-immunization modulates hypocretin/orexin neuronal functions. Sleep 40, 1–10 (2017).
Seifinejad, A. et al. Epigenetic silencing of selected hypothalamic neuropeptides in narcolepsy with cataplexy. Proc. Natl Acad. Sci. USA 120, e2220911120 (2023). This study provides indirect evidence to suggest that the hypocretin-producing neurons could be preserved but silenced in narcolepsy, an intriguing and new concept.
pubmed: 37126681
pmcid: 10175817
doi: 10.1073/pnas.2220911120
Bien, C. G. Limbic encephalitis. Handb. Clin. Neurol. 187, 467–487 (2022).
pubmed: 35964988
doi: 10.1016/B978-0-12-823493-8.00024-9
Jia, Y. et al. LGI1 antibody-associated encephalitis without evidence of inflammation in CSF and brain MRI. Acta Neurol. Belg. https://doi.org/10.1007/s13760-022-01955-8 (2023).
doi: 10.1007/s13760-022-01955-8
pubmed: 37046133
Ostkamp, P. et al. A single-cell analysis framework allows for characterization of CSF leukocytes and their tissue of origin in multiple sclerosis. Sci. Transl. Med. 14, eadc9778 (2022).
pubmed: 36449599
doi: 10.1126/scitranslmed.adc9778
Huang, J. et al. Assessing the preanalytical variability of plasma and cerebrospinal fluid processing and its effects on inflammation-related protein biomarkers. Mol. Cell Proteom. 20, 100157 (2021).
doi: 10.1016/j.mcpro.2021.100157
Devine, M. F. & St Louis, E. K. Sleep disturbances associated with neurological autoimmunity. Neurotherapeutics 18, 181–201 (2021).
pubmed: 33786802
pmcid: 8116412
doi: 10.1007/s13311-021-01020-x
Bassetti, C. L. A. et al. European guideline and expert statements on the management of narcolepsy in adults and children. J. Sleep. Res. 30, e13387 (2021).
pubmed: 34173288
doi: 10.1111/jsr.13387
Maski, K. et al. Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine systematic review, meta-analysis, and GRADE assessment. J. Clin. Sleep. Med. 17, 1895–1945 (2021).
pubmed: 34743790
pmcid: 8636345
doi: 10.5664/jcsm.9326
Lecendreux, M., Maret, S., Bassetti, C., Mouren, M.-C. & Tafti, M. Clinical efficacy of high-dose intravenous immunoglobulins near the onset of narcolepsy in a 10-year-old boy. J. Sleep. Res. 12, 347–348 (2003).
pubmed: 14633248
doi: 10.1046/j.1365-2869.2003.00380.x
Dauvilliers, Y., Carlander, B., Rivier, F., Touchon, J. & Tafti, M. Successful management of cataplexy with intravenous immunoglobulins at narcolepsy onset. Ann. Neurol. 56, 905–908 (2004).
pubmed: 15562415
doi: 10.1002/ana.20339
Valko, P. O., Khatami, R., Baumann, C. R. & Bassetti, C. L. No persistent effect of intravenous immunoglobulins in patients with narcolepsy with cataplexy. J. Neurol. 255, 1900–1903 (2008).
pubmed: 18825431
doi: 10.1007/s00415-008-0996-2
Dauvilliers, Y., Abril, B., Mas, E., Michel, F. & Tafti, M. Normalization of hypocretin-1 in narcolepsy after intravenous immunoglobulin treatment. Neurology 73, 1333–1334 (2009).
pubmed: 19841387
doi: 10.1212/WNL.0b013e3181bd1344
Chen, W., Black, J., Call, P. & Mignot, E. Late-onset narcolepsy presenting as rapidly progressing muscle weakness: response to plasmapheresis. Ann. Neurol. 58, 489–490 (2005).
pubmed: 16130098
doi: 10.1002/ana.20603
Hecht, M. et al. Report of a case of immunosuppression with prednisone in an 8-year-old boy with an acute onset of hypocretin-deficiency narcolepsy. Sleep 26, 809–810 (2003).
pubmed: 14655912
doi: 10.1093/sleep/26.7.809
Katsavos, S. & Coles, A. Alemtuzumab as treatment for multiple sclerosis. Cold Spring Harb. Perspect. Med. 8, a032029 (2018).
pubmed: 29500306
pmcid: 6169984
doi: 10.1101/cshperspect.a032029
Donjacour, C. E. H. M. & Lammers, G. J. A remarkable effect of alemtuzumab in a patient suffering from narcolepsy with cataplexy. J. Sleep. Res. 21, 479–480 (2012).
pubmed: 22142323
doi: 10.1111/j.1365-2869.2011.00985.x
Ding, Q., Xiao, F., Dong, X., Zhang, J. & Han, F. Treatment with immune modulators in a child with recent-onset type 1 narcolepsy. Sleep. Breath. 25, 387–389 (2021).
pubmed: 32813213
doi: 10.1007/s11325-020-02034-z
Wasling, P., Malmeström, C. & Blennow, K. CSF orexin-A levels after rituximab treatment in recent onset narcolepsy type 1. Neurol. Neuroimmunol. Neuroinflamm. 6, e613 (2019).
pubmed: 31484686
pmcid: 6745716
doi: 10.1212/NXI.0000000000000613
Scammell, T. E. et al. Treatment of narcolepsy with natalizumab. Sleep 43, zsaa050 (2020).
pubmed: 32249922
doi: 10.1093/sleep/zsaa050
Barateau, L., Liblau, R., Peyron, C. & Dauvilliers, Y. Narcolepsy type 1 as an autoimmune disorder: evidence, and implications for pharmacological treatment. CNS Drugs 31, 821–834 (2017).
pubmed: 28940143
doi: 10.1007/s40263-017-0464-6
Lopez, R. et al. Temporal changes in the cerebrospinal fluid level of hypocretin-1 and histamine in narcolepsy. Sleep 40, zsw010 (2017).
pubmed: 28364477
pmcid: 5806580
doi: 10.1093/sleep/zsw010
Jackson, M. W., Spencer, N. J., Reed, J. H., Smith, A. J. F. & Gordon, T. P. Potentiation of a functional autoantibody in narcolepsy by a cholinesterase inhibitor. Lab. Invest. 89, 1332–1339 (2009).
pubmed: 19806080
doi: 10.1038/labinvest.2009.108
Jackson, M. W., Reed, J. H., Smith, A. J. F. & Gordon, T. P. An autoantibody in narcolepsy disrupts colonic migrating motor complexes. J. Neurosci. 28, 13303–13309 (2008).
pubmed: 19052222
pmcid: 6671602
doi: 10.1523/JNEUROSCI.4489-08.2008
van der Heide, A. et al. Immunohistochemical screening for antibodies in recent onset type 1 narcolepsy and after H1N1 vaccination. J. Neuroimmunol. 283, 58–62 (2015).
pubmed: 26004157
doi: 10.1016/j.jneuroim.2015.04.008
Giannoccaro, M. P. et al. Antibodies against hypocretin receptor 2 are rare in narcolepsy. Sleep https://doi.org/10.1093/sleep/zsw056 (2017).
doi: 10.1093/sleep/zsw056
pubmed: 28364500
Häggmark-Månberg, A. et al. Autoantibody targets in vaccine-associated narcolepsy. Autoimmunity 49, 421–433 (2016).
pubmed: 27206786
doi: 10.1080/08916934.2016.1183655
Lampeter, E. F. et al. Transfer of insulin-dependent diabetes between HLA-identical siblings by bone marrow transplantation. Lancet 341, 1243–1244 (1993).
pubmed: 8098394
doi: 10.1016/0140-6736(93)91148-F
Anderson, M. S. & Bluestone, J. A. The NOD mouse: a model of immune dysregulation. Annu. Rev. Immunol. 23, 447–485 (2005).
pubmed: 15771578
doi: 10.1146/annurev.immunol.23.021704.115643
Ben-Nun, A. et al. From classic to spontaneous and humanized models of multiple sclerosis: impact on understanding pathogenesis and drug development. J. Autoimmun. 54, 33–50 (2014).
pubmed: 25175979
doi: 10.1016/j.jaut.2014.06.004
Griffin, A. C., Zhao, W., Wegmann, K. W. & Hickley, W. F. Experimental autoimmune insulitis. Induction by T lymphocytes specific for a peptide of proinsulin. Am. J. Pathol. 147, 845–857 (1995).
pubmed: 7545875
pmcid: 1870961
Houeiss, P., Boitard, C. & Luce, S. Preclinical models to evaluate the human response to autoantigen and antigen-specific immunotherapy in human type 1 diabetes. Front. Endocrinol. 13, 883000 (2022).
doi: 10.3389/fendo.2022.883000
Steinman, L., Patarca, R. & Haseltine, W. Experimental encephalomyelitis at age 90, still relevant and elucidating how viruses trigger disease. J. Exp. Med. 220, e20221322 (2023).
pubmed: 36652203
pmcid: 9880878
doi: 10.1084/jem.20221322
Coppieters, K. T. et al. Demonstration of islet-autoreactive CD8 T cells in insulitic lesions from recent onset and long-term type 1 diabetes patients. J. Exp. Med. 209, 51–60 (2012).
pubmed: 22213807
pmcid: 3260877
doi: 10.1084/jem.20111187
Bender, C., Rodriguez-Calvo, T., Amirian, N., Coppieters, K. T. & von Herrath, M. G. The healthy exocrine pancreas contains preproinsulin-specific CD8 T cells that attack islets in type 1 diabetes. Sci. Adv. 6, eabc5586 (2020).
pubmed: 33067232
pmcid: 7567597
doi: 10.1126/sciadv.abc5586
Jelcic, I. et al. Memory B cells activate brain-homing, autoreactive CD4
pubmed: 30173916
pmcid: 6191934
doi: 10.1016/j.cell.2018.08.011
Lanz, T. V. et al. Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM. Nature 603, 321–327 (2022). This elegant study demonstrates that intrathecal B cells from persons with multiple sclerosis can react to both an Epstein–Barr virus protein and a CNS autoantigen, providing evidence for molecular mimicry.
pubmed: 35073561
pmcid: 9382663
doi: 10.1038/s41586-022-04432-7
Culina, S. et al. Islet-reactive CD8
pubmed: 29429978
pmcid: 5874133
doi: 10.1126/sciimmunol.aao4013
Hohlfeld, R. & Liblau, R. S. Toward identification of personalized immunological profiles in multiple sclerosis. Sci. Adv. 8, eabq4849 (2022).
pubmed: 35476442
doi: 10.1126/sciadv.abq4849
Popoviciu, M. S. et al. Type 1 diabetes mellitus and autoimmune diseases: a critical review of the association and the application of personalized medicine. J. Pers. Med. 13, 422 (2023).
pubmed: 36983604
pmcid: 10056161
doi: 10.3390/jpm13030422
Ramagopalan, S. V. et al. Autoimmune disease in families with multiple sclerosis: a population-based study. Lancet Neurol. 6, 604–610 (2007).
pubmed: 17560172
doi: 10.1016/S1474-4422(07)70132-1
Barateau, L. et al. Comorbidity between central disorders of hypersomnolence and immune-based disorders. Neurology 88, 93–100 (2017).
pubmed: 27864522
doi: 10.1212/WNL.0000000000003432
Noble, J. A. Immunogenetics of type 1 diabetes: a comprehensive review. J. Autoimmun. 64, 101–112 (2015).
pubmed: 26272854
doi: 10.1016/j.jaut.2015.07.014
International Multiple Sclerosis Genetics Consortium. Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility. Science 365, eaav7188 (2019).
pmcid: 7241648
doi: 10.1126/science.aav7188
Kundu, K. et al. Genetic associations at regulatory phenotypes improve fine-mapping of causal variants for 12 immune-mediated diseases. Nat. Genet. 54, 251–262 (2022).
pubmed: 35288711
doi: 10.1038/s41588-022-01025-y
Herold, K. C. et al. An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes. N. Engl. J. Med. 381, 603–613 (2019).
pubmed: 31180194
pmcid: 6776880
doi: 10.1056/NEJMoa1902226
Montalban, X. et al. ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis. Mult. Scler. 24, 96–120 (2018).
pubmed: 29353550
doi: 10.1177/1352458517751049
Ollila, H. M., Fernandez-Vina, M. & Mignot, E. HLA-DQ allele competition in narcolepsy: a comment on Tafti et al. DQB1 locus alone explains most of the risk and protection in narcolepsy with cataplexy in Europe. Sleep 38, 147–151 (2015). This publication proposes a new genetic model to explain the risk of narcolepsy associated with HLA-DQ, known as allele competition.
pubmed: 25325462
pmcid: 4262948
doi: 10.5665/sleep.4342
Dendrou, C. A., Petersen, J., Rossjohn, J. & Fugger, L. HLA variation and disease. Nat. Rev. Immunol. 18, 325–339 (2018).
pubmed: 29292391
doi: 10.1038/nri.2017.143
Siebold, C. et al. Crystal structure of HLA-DQ0602 that protects against type 1 diabetes and confers strong susceptibility to narcolepsy. Proc. Natl Acad. Sci. USA 101, 1999–2004 (2004).
pubmed: 14769912
pmcid: 357041
doi: 10.1073/pnas.0308458100
Iversen, R. & Sollid, L. M. The immunobiology and pathogenesis of celiac disease. Annu. Rev. Pathol. 18, 47–70 (2023).
pubmed: 36067801
doi: 10.1146/annurev-pathmechdis-031521-032634
Curran, A. M., Naik, P., Giles, J. T. & Darrah, E. PAD enzymes in rheumatoid arthritis: pathogenic effectors and autoimmune targets. Nat. Rev. Rheumatol. 16, 301–315 (2020).
pubmed: 32341463
doi: 10.1038/s41584-020-0409-1
Zhai, Y. et al. Cysteine carboxyethylation generates neoantigens to induce HLA-restricted autoimmunity. Science 379, eabg2482 (2023).
pubmed: 36927018
doi: 10.1126/science.abg2482
Raposo, B. et al. T cells specific for post-translational modifications escape intrathymic tolerance induction. Nat. Commun. 9, 353 (2018).
pubmed: 29367624
pmcid: 5783942
doi: 10.1038/s41467-017-02763-y
Mentzer, A. J. et al. Human leukocyte antigen alleles associate with COVID-19 vaccine immunogenicity and risk of breakthrough infection. Nat. Med. 29, 147–157 (2023).
pubmed: 36228659
doi: 10.1038/s41591-022-02078-6
Sundqvist, E. et al. JC polyomavirus infection is strongly controlled by human leucocyte antigen class II variants. PLoS Pathog. 10, e1004084 (2014).
pubmed: 24763718
pmcid: 3999271
doi: 10.1371/journal.ppat.1004084
Ooi, J. D. et al. Dominant protection from HLA-linked autoimmunity by antigen-specific regulatory T cells. Nature 545, 243–247 (2017).
pubmed: 28467828
pmcid: 5903850
doi: 10.1038/nature22329
Hsiao, C.-C. et al. Osteopontin associates with brain TRM-cell transcriptome and compartmentalization in donors with and without multiple sclerosis. iScience 26, 105785 (2023).
pubmed: 36594029
doi: 10.1016/j.isci.2022.105785
Lake, B. B. et al. Integrative single-cell analysis of transcriptional and epigenetic states in the human adult brain. Nat. Biotechnol. 36, 70–80 (2018).
pubmed: 29227469
doi: 10.1038/nbt.4038
Williams, C. G., Lee, H. J., Asatsuma, T., Vento-Tormo, R. & Haque, A. An introduction to spatial transcriptomics for biomedical research. Genome Med. 14, 68 (2022).
pubmed: 35761361
pmcid: 9238181
doi: 10.1186/s13073-022-01075-1
Ayoglu, B. et al. Anoctamin 2 identified as an autoimmune target in multiple sclerosis. Proc. Natl Acad. Sci. USA 113, 2188–2193 (2016).
pubmed: 26862169
pmcid: 4776531
doi: 10.1073/pnas.1518553113
Talucci, I. & Maric, H. M. Peptide microarrays for studying autoantibodies in neurological disease. Methods Mol. Biol. 2578, 17–25 (2023).
pubmed: 36152277
doi: 10.1007/978-1-0716-2732-7_2
Baker, R. L. et al. Hybrid insulin peptides are autoantigens in type 1 diabetes. Diabetes 68, 1830–1840 (2019).
pubmed: 31175101
pmcid: 6702640
doi: 10.2337/db19-0128
Tran, M. T. et al. T cell receptor recognition of hybrid insulin peptides bound to HLA-DQ8. Nat. Commun. 12, 5110 (2021).
pubmed: 34433824
pmcid: 8387461
doi: 10.1038/s41467-021-25404-x
Axisa, P.-P. et al. A multiple sclerosis-protective coding variant reveals an essential role for HDAC7 in regulatory T cells. Sci. Transl. Med. 14, eabl3651 (2022).
pubmed: 36516268
doi: 10.1126/scitranslmed.abl3651